Shanghai Shyndec Pharmaceutical (600420.SH) subsidiary obtained drug registration certificate for Ketamine Hydrochloride Injection.

Shanghai Shyndec Pharmaceutical (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd. (referred to as National Pharmaceutical Industry), has received the Drug Registration Certificate for Ketamine Hydrochloride Injection issued by the National Medical Products Administration. This registration certificate is equivalent to passing the consistency evaluation, which will further enrich the company's portfolio of anesthesia and analgesic products, and enhance the company's comprehensive market competitiveness in the relevant therapeutic area. It is reported that Ketamine is a classic intravenous anesthetic drug, first developed by Parke-Davis in 1962, with both anesthetic and analgesic effects, and widely used in the fields of anesthesia and critical care. Ketamine Hydrochloride Injection was approved by the FDA in the United States in February 1970, and is a intravenous general anesthetic used clinically as a surgical anesthetic or induction agent, suitable for various superficial, short minor surgery anesthesia, diagnostic examination anesthesia for uncooperative children, and general anesthesia, belonging to the first class of psychotropic drugs.